CIK: 0001595430
Total reported value
$1.4B
Reporting period: 2026-03-31 · Number of holdings: 17
Nextech Invest, Ltd. disclosed 17 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.4B and a quarterly turnover rate of 35.2%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "N"
Nextech Invest, Ltd.'s disclosed holdings carry a Herfindahl concentration index of 0.304 — mathematically equivalent to about 3 equally-sized positions, well below its 17 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 2.10), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 52% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim RVMD
0.0% $133.8M
Add TNGX
0.0% $87.6M
Add ALMS
+21.4% $49.5M
Trim ZYME
0.0% -$1.4M
Trim 29286M105
+9.4% -$3.4M
Add ORIC
0.0% $32.2M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | Stock-Healthcare | 52.02% | -6.51% | — | |
| 2 | TYRA | Tyra Biosciences INC | Stock-Other | 10.93% | +0.62% | — | |
| 3 | TNGX | Tango Therapeutics INC | Stock-Other | 10.70% | +4.48% | — | |
| 4 | ORIC | Oric Pharmaceuticals INC | Stock-Other | 6.39% | +0.73% | — | |
| 5 | ALMS | Alumis INC | Stock-Other | 5.49% | +2.74% | +21.43% | |
| 6 | RLAY | Relay Therapeutics INC | Stock-Other | 3.87% | +0.02% | +17.55% | |
| 7 | ZYME | Zymeworks INC | Stock-Other | 1.96% | -0.88% | — | |
| 8 | KYMR | Kymera Therapeutics INC | Stock-Other | 1.63% | -0.47% | — | |
| 9 | CTMX | Cytomx Therapeutics INC | Stock-Other | 1.47% | +1.47% | NEW | |
| 10 | CNTX | Context Therapeutics INC | Stock-Other | 1.37% | +0.32% | — | |
| 11 | CGEM | Cullinan Therapeutics INC | Stock-Other | 1.14% | — | — | |
| 12 | ✓ | Engene Holdings INC | Stock-Other | 1.11% | -0.75% | +9.41% | |
| 13 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 0.46% | +0.46% | NEW | |
| 14 | ARVN | Arvinas INC | Stock-Other | 0.40% | -0.22% | — | |
| 15 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.35% | -0.21% | — | |
| 16 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 0.35% | -0.07% | +8.95% | |
| 17 | SPRY | Ars Pharmaceuticals INC | Stock-Other | 0.35% | -0.39% | -7.57% |
Performance for Q3 2026
+23.5%
Performance Last 4 Quarters
+333.3%
Based on 76% of reported portfolio value with available pricing
Nextech Invest, Ltd.'s most significant position changes for 2026-03-31: New buy: Cytomx Therapeutics INC (CTMX); Sold out: Mersana Therapeutics INC (MRSN); New buy: Corvus Pharmaceuticals INC (CRVS); Add: Alumis INC (ALMS) — shares +21.43%; Add: Engene Holdings INC — shares +9.41%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics INC | +4.5% | — | Unchanged |
| 2 | ALMS | Alumis INC | +2.7% | +21.43% | Add |
| 3 | ORIC | Oric Pharmaceuticals INC | +0.7% | — | Unchanged |
| 4 | TYRA | Tyra Biosciences INC | +0.6% | — | Unchanged |
| 5 | CNTX | Context Therapeutics INC | +0.3% | — | Unchanged |
| 6 | RLAY | Relay Therapeutics INC | 0% | +17.55% | Add |
| 7 | CGEM | Cullinan Therapeutics INC | — | — | Unchanged |
| 8 | GLUE | Monte Rosa Therapeutics INC | -0.1% | +8.95% | Add |
| 9 | SLN | Silence Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 10 | ARVN | Arvinas INC | -0.2% | — | Unchanged |
| 11 | SPRY | Ars Pharmaceuticals INC | -0.4% | -7.57% | Trim |
| 12 | KYMR | Kymera Therapeutics INC | -0.5% | — | Unchanged |
| 13 | ✓ | Engene Holdings INC | -0.8% | +9.41% | Add |
| 14 | ZYME | Zymeworks INC | -0.9% | — | Unchanged |
| 15 | RVMD | Revolution Medicines INC | -6.5% | — | Unchanged |
| 16 | CTMX | Cytomx Therapeutics INC | — | NEW | New buy |
| 17 | MRSN | Mersana Therapeutics INC | — | EXIT | Sold out |
| 18 | CRVS | Corvus Pharmaceuticals INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001456114
Total reported value
$1.4B
835 stks
2022-06-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001830600
Total reported value
$1.4B
2,676 stks
2022-09-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001164478
Total reported value
$1.4B
221 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001911010
Total reported value
$616.4M
15 stks
2024-12-31
Stale — no recent filing
3 of the top 5 holdings overlap, including Revolution Medicines INC
CIK 0002092021
Total reported value
$315.1M
114 stks
2026-03-31
3 of the top 5 holdings overlap, including Tango Therapeutics INC
CIK 0001678378
Total reported value
$468.9M
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Revolution Medicines INC